When does the gefitinib patent expire (and what does “expiry” mean)?
“Patent expiry” can refer to different legal deadlines. The drug may face several layers of exclusivity:
- The patent covering the active ingredient (gefitinib) ending.
- Later patents covering specific formulations, dosing regimens, or combinations.
- Regulatory exclusivity that can delay generic entry even after a patent ends (depends on country).
The provided information does not include the specific jurisdictions, patent numbers, or filing/expiry dates needed to state an exact expiry date for gefitinib.
Which countries’ timelines matter for gefitinib?
Patent and exclusivity timelines are country-specific. The same medicine can have different expiry dates in:
- The US (with different patent-term adjustments and trial/approval pathways).
- The EU/UK (with separate patent and regulatory exclusivity rules).
- India, Japan, Canada, and other markets (each with its own patent register and drug-specific protections).
To give a concrete expiry date, you typically need at least one of: the country/market, the product name (brand and strength), and the patent numbers listed on the patent register for that product.
What can delay generic entry after a patent expires?
Even after the “main” patent ends, generic or biosimilar launch can still be delayed by:
- Remaining patents on formulations, polymorphs, or use claims.
- Litigation around patent validity/infringement.
- Regulatory or data exclusivity periods tied to marketing approval in that country.
How to find the exact gefitinib patent expiry date
The most reliable approach is to check the official patent listings for your target market:
- US: FDA’s Orange Book for gefitinib products and linked patents/expiration dates.
- EU/UK: national patent registers and any relevant drug product protection databases.
- Other markets: the local patent office registers and drug regulatory exclusivity records.
What I need to answer precisely
Tell me:
1) Which country/region you care about (US, EU, UK, India, etc.), and
2) The gefitinib product/brand (if you know it) or the strength (e.g., 250 mg tablets), and
3) Whether you mean patent expiry for the active ingredient or “last remaining exclusivity” for generic entry.
With that, I can map the likely protection layers and identify the expected expiry date(s).